RP
ANIK icon

Riverwater Partners’s Anika Therapeutics ANIK Stock Holding History

Riverwater Partners’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-101,996
Closed -$2.55M – 215
2024
Q3 		$2.55M Buy
101,996
+86,037
+539% +$2.23M 1.27% 15
2024
Q2 		$404K Sell
15,959
-1,703
-10% -$44.1K 0.3% 102
2024
Q1 		$449K Sell
17,662
-46
-0.3% -$1.11K 0.33% 87
2023
Q4 		$401K Buy
17,708
+111
+0.6% +$2.3K 0.32% 95
2023
Q3 		$328K Buy
17,597
+7,813
+80% +$162K 0.3% 113
2023
Q2 		$254K Hold
9,784
– – 0.23% 151
2023
Q1 		$281K Buy
9,784
+6
+0.1% +$179 0.26% 127
2022
Q4 		$289K Buy
+9,778
New +$278K 0.25% 131
2022
Q3 		– Sell
-12,466
Closed -$278K – 189
2022
Q2 		$278K Buy
12,466
+96
+0.8% +$2.14K 0.28% 127
2022
Q1 		$311K Buy
12,370
+3,274
+36% +$99.8K 0.51% 81
2021
Q4 		$326K Buy
+9,096
New +$364K 0.29% 133

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Riverwater Partners's ANIK Position: Q4 2024 in Review

Riverwater Partners sold out of Anika Therapeutics (ANIK) in Q4 2024, closing a stake of 101,996 shares — an estimated $2.55M sold.

Riverwater Partners first reported a position in ANIK in Q4 2021 and held it in 11 quarters. The position peaked at $2.55M in Q3 2024. 109 funds tracked by Wall St. Rank hold ANIK as of Q4 2024.

  • Riverwater Partners reported no remaining Anika Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Riverwater Partners sold 101,996 Anika Therapeutics shares in Q4 2024, an estimated $2.55M.
  • Riverwater Partners first reported a position in Anika Therapeutics in Q4 2021 and held it in 11 quarters.
  • Riverwater Partners's Anika Therapeutics position peaked at $2.55M in Q3 2024.
  • 109 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2024.

Based on Riverwater Partners's 13F filing for Q4 2024, filed 13 Feb 2025.